LF5 was associated with the presence of somatic cancer driver mutations in TP53 (Discovery: P = 0.025; Validation: P = 6.0 × 10−10), as well as with changes in the expression of cell cycle genes and cycling cells (all P < 0.001; Figs. 2B,C and EV3B,C). This evidence concerns the gene TP53 and cancer.